A Drug Interaction Study to Assess the Effect of LY2603618 on the Metabolic Pathway of Desipramine
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effect LY2603618 on a protein [enzyme cytochrome P
(CYP) 2D6] which is involved in the metabolic pathway of Desipramine in participants with
cancer. This is a drug interaction study so the treatment of the disease will not be the main
purpose of the study.
The study involves two single doses of 50 milligrams (mg), 1 tablet by mouth, on Day 1 of
Period 1 and 2. In Period 1 Desipramine will be administered alone. In Period 2 Desipramine
will be administered in combination with LY2603618. LY2603618 will be administered as a 275mg
intravenous (IV) infusion over 1 hour (hr).
Desipramine will be administered at the end of the LY2603618 infusion. Information about any
side effects that may occur will also be collected.